ATE421883T1 - Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline - Google Patents

Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Info

Publication number
ATE421883T1
ATE421883T1 AT99969030T AT99969030T ATE421883T1 AT E421883 T1 ATE421883 T1 AT E421883T1 AT 99969030 T AT99969030 T AT 99969030T AT 99969030 T AT99969030 T AT 99969030T AT E421883 T1 ATE421883 T1 AT E421883T1
Authority
AT
Austria
Prior art keywords
glucan
compositions containing
specific immunoglobulins
containing beta
beta
Prior art date
Application number
AT99969030T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Fattom
Robert Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of ATE421883T1 publication Critical patent/ATE421883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99969030T 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline ATE421883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
ATE421883T1 true ATE421883T1 (de) 2009-02-15

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969030T ATE421883T1 (de) 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Country Status (11)

Country Link
US (1) US6355625B1 (de)
EP (1) EP1121135B1 (de)
AT (1) ATE421883T1 (de)
AU (1) AU6033299A (de)
CA (1) CA2344166C (de)
CY (1) CY1109437T1 (de)
DE (1) DE69940371D1 (de)
DK (1) DK1121135T3 (de)
ES (1) ES2321892T3 (de)
PT (1) PT1121135E (de)
WO (1) WO2000015238A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2002058711A1 (en) 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
AU2003268486A1 (en) * 2002-09-04 2004-03-29 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US20090169557A1 (en) * 2004-05-10 2009-07-02 Biopolymer Engineering, Inc. D/B/A Biothera Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
EP2298340B1 (de) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1850867A1 (de) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Verfahren zur behandlung einer infektion mit staphylococcus aureus
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
EP1917019A2 (de) * 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Kombination eines beta-glucans und eines egf-rezeptor-antagonisten zur krebs- und infektionsbehandlung
CN101184780B (zh) * 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
US20090074755A1 (en) 2005-06-13 2009-03-19 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
US20090053235A1 (en) 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
EP2208787A1 (de) 2009-01-19 2010-07-21 Université de Liège Rekombinantes alpha-Hämolysin-Polypeptid von Staphylococcus aureus, mit einer Deletion in der Stammdomäne und eingefügten heterologen Sequenzen
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
EP3281947B1 (de) 2009-04-03 2020-02-12 The University of Chicago Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
EP4015523A1 (de) 2010-05-05 2022-06-22 New York University Staphylococcus-aureus-leukocidine sowie therapeutische zusammensetzungen daraus und verwendungen davon
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112013032774B1 (pt) 2011-06-19 2020-05-05 Univ New York composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso
AU2012273125B2 (en) 2011-06-19 2017-05-25 New York University Leukotoxin E/D as a new anti-inflammatory agent and microbicide
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
NZ702282A (en) 2012-04-26 2016-07-29 Univ Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
EP3363462A1 (de) * 2012-04-30 2018-08-22 Biothera, Inc. Zusammensetzungen und verfahren für beta-glucan-immuntherapie
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3229833A1 (de) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Behandlungsverfahren
AU2017218768B2 (en) 2016-02-12 2022-03-31 Janssen Pharmaceuticals, Inc. Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
US20220339248A1 (en) 2019-06-19 2022-10-27 The Research Foundation For The State University Of New York Methods for treating neointimal hyperlasia using f11r/jam-a inhibitors
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
EP4504241A1 (de) 2022-04-01 2025-02-12 Icahn School of Medicine at Mount Sinai Behandlung von orthopädischen verletzungen mit einem vektor zur ansteuerung der expression saurer ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
CA2123811C (en) * 1991-11-22 2005-07-05 Ali Ibrahim Fattom Type i and type ii surface antigens associated with staphylococcus epidermidis
WO1996014873A2 (en) 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
ES2321892T3 (es) 2009-06-12
DK1121135T3 (da) 2009-03-23
WO2000015238A1 (en) 2000-03-23
EP1121135A4 (de) 2005-03-16
CA2344166C (en) 2008-11-18
WO2000015238B1 (en) 2000-08-31
EP1121135A1 (de) 2001-08-08
WO2000015238A9 (en) 2000-10-12
CA2344166A1 (en) 2000-03-23
US6355625B1 (en) 2002-03-12
EP1121135B1 (de) 2009-01-28
AU6033299A (en) 2000-04-03
DE69940371D1 (de) 2009-03-19
PT1121135E (pt) 2009-03-05
CY1109437T1 (el) 2014-08-13

Similar Documents

Publication Publication Date Title
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
TR200000059T2 (tr) Piridin türevleri
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
DE59709414D1 (de) Oxyiminopregnancarbolactone
ATE457998T1 (de) Abgeschwächte mikroorganismen für die behandlung von infektionen
CO5210911A1 (es) Trifluorbutenos nematicidas
DE60033649D1 (de) Verbindungen und therapeutische methoden
ES2009140A6 (es) Un metodo de produccion de anticuerpos monoclonales humanos de proteccion cruzada y de composiciones que los contienen.
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
EA200200704A1 (ru) Ослабленные микроорганизмы для лечения инфекции
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.
NO982151D0 (no) Hemoregulatoriske forbindelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121135

Country of ref document: EP